Phaseline

Companies › Stelexis BioSciences

Stelexis BioSciences: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Eganelisib
PI3-kinase p110-gamma subunit inhibitor
PIK3CGPhase 1AML, Adult; Leukemia, MyeloidDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06533761EganelisibPhase 1AML, AdultOncologyDec 2027
NCT07439211EganelisibPhase 1Leukemia, MyeloidOncologyFeb 2028

Targets

PIK3CG (1)

Companies with the same targets

Restorbio Celcuity Eli Lilly Rhizen Pharmaceuticals Sovargen SecuraBio

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.